Overview:
Our brain not only processes sensory signals but also makes predictions about the world. Generating and updating predictions are essential for our survival in a rapidly changing environment. Multiple brain regions including the cerebellum and the cortex are thought to be involved in the processing of prediction signals (aka predictive processing). However, it is not clear what circuit mechanisms and computations underlie predictive processing in each region, and how the cortical and cerebellar prediction signals interact to support cognitive and sensorimotor behavior. Our lab is interested in figuring out these questions by using advanced experimental and computational techniques in systems neuroscience.

The Panitch lab research has focused on the extracellular matrix (ECM) and how matrix signals affect tissue regeneration, including nerve regeneration, wound healing and angiogenesis, cartilage and vascular. More recently, the lab has focused on the proteoglycan component of the ECM. Proteoglycans are critical components of tissue function. They influence matrix organization, the viscoelastic properties of the matrix, access of enzymes to the matrix and serve as a protective barrier as in the case of the glycocalyx. Proteoglycans are difficult to synthesize because of the complex post translational modifications and the complexity of carbohydrate chemistry. The Panitch laboratory has demonstrated that proteoglycan function can largely be recapitulated by conjugating short, bioactive peptide sequences to GAGs. The peptide sequences direct the GAG to its target and ensure that it is held in place, similarly to how native proteoglycans function. The lab has used proteoglycan mimetic strategies to develop therapeutics to treat osteoarthritis, improve wound healing, and treat diseased blood vessels.

 As a physician scientist, Dr. Bauser-Heaton's clinical and research interests are focused on pulmonary vascular disease. Our 3D bioprinted disease modeling allows study of patient specific geometries and cell types for potential therapeutic targets. Through collaborations with several IBB members, we have created a pipeline for disease modeling that includes computational fluid dynamics, particle image velocity measurement of shear stress, additive manufacturing and iPSC utilization. 

Saurabh Sinha received his Ph.D. in Computer Science from the University of Washington, Seattle, in 2002, and after post-doctoral work at the Rockefeller University with Eric Siggia, he joined the faculty of the University of Illinois, Urbana-Champaign, in 2005, where he held the positions of Founder Professor in Computer Science and Director of Computational Genomics in the Carl R. Woese Institute for Genomic Biology until 2022. He joined Georgia Institute of Technology in 2022, as Wallace H. Coulter Distinguished Chair in Biomedical Engineering, with joint appointments in Biomedical Engineering and Industrial & Systems Engineering. Sinha’s research is in the area of bioinformatics, with a focus on regulatory genomics and systems biology. Sinha is an NSF CAREER award recipient and has been funded by NIH, NSF and USDA. He co-directed an NIH BD2K Center of Excellence and was a thrust lead in the NSF AI Institute at UIUC. He led the educational program of the Mayo Clinic-University of Illinois Alliance, and co-led data science education for the Carle Illinois College of Medicine. Sinha has served as Program co-Chair of the annual RECOMB Regulatory and Systems Genomics conference and served on the Board of Directors for the International Society for Computational Biology (2018-2021). He was a recipient of the University Scholar award of the University of Illinois, and selected as a Fellow of the AIMBE in 2018.

Vida Jamali earned her Ph.D. in chemical and biomolecular engineering from Rice University under the guidance of Professor Matteo Pasquali and her B.S. in chemical engineering from Sharif University of Technology. Jamali was a postdoctoral researcher in Professor Paul Alivisato's lab at UC Berkeley and Kavli Energy Nanoscience Institute before joining Georgia Tech. The Jamali Research Group uses experimental, theoretical, and computational tools such as liquid phase transmission electron microscopy, rheology, statistical and colloidal thermodynamics, and machine learning to study the underlying physical principles that govern the dynamics, statistics, mechanics, and self-organization of nanostructured soft materials, in and out of thermal equilibrium, from both fundamental and technological aspects.

Alex Abramson is an assistant professor in the School of Chemical and Biomolecular Engineering at Georgia Tech. His research, which focuses on drug delivery and bioelectronic therapeutics, has been featured in news outlets such as The New York Times, NPR, and Wired. Abramson has received several recognitions for scientific innovation, including being named a member of the Forbes 30 Under 30 Science List and the MIT Technology Review Innovators Under 35 List. He is passionate about translating scientific endeavors from bench to bedside. Large pharmaceutical companies have exclusively licensed a portfolio of his patents to bring into clinical trials, and Abramson serves as a scientific advisor overseeing their commercialization. In addition to his scientific endeavors, Abramson plays an active role in his community by leading diversity and inclusion efforts on campus and volunteering as a STEM tutor to local students.

Abramson received a B.S. in chemical and biomolecular engineering from Johns Hopkins University and a Ph.D. in chemical engineering from MIT as an NSF Graduate Research Fellow under the direction of Professors Robert Langer and Giovanni Traverso. He conducted postdoctoral work at Stanford University as an NIH fellow with Professors Zhenan Bao and the late Sanjiv S. Gambhir.

The Abramson Lab develops ingestible, implantable, and wearable robotic therapeutic devices that solve key healthcare problems and provide measurable therapeutic outcomes. Our translationally focused research spans a multitude of areas, including (1) drug delivery devices for optimal drug adherence, (2) soft materials for bioelectronic sensors and therapeutics, and (3) preclinical drug screening technologies.

Michelle’s research is themed around designing and characterizing the surface chemical properties of synthetic and natural polymer systems. They will be used to develop multifunctional biomaterial substrates for regenerative medicine, cancer treatment, and personal care products. The goals of the Gaines Lab are achieved by marrying Polymer Synthesis, Materials Science, Cell Biology & Spectroscopy.

Laura Hansen received her BS in Bioengineering from the University of Pittsburgh and Ph.D. in Bioengineering from the Georgia Institute of Technology, where she studied the mechanics of blood vessel walls and changes associated with different disease states. She then completed her post-doctoral fellowship studying the RAGE receptor in peripheral artery disease at Emory University in Cardiology. She is currently an Assistant Professor in the Department of Medicine and Division of Cardiology and program faculty in Biomedical Engineering and Molecular and Systems Pharmacology. Hansen’s lab studies the interactions between satellite cells and the vasculature. Satellite cells are skeletal muscle progenitor cells that are known to play an important role in muscle repair after injury and adaptation to exercise. However, the Hansen lab focuses on a previously underexplored role of satellite cells in vascular growth. They have found that satellite cells, when activated, produced a number of chemoattractant growth factors that drive the migration of vascular smooth muscle and endothelial cells which in an important factor in the growth and development of blood vessels. This area is of particular interest in the context of peripheral artery disease, where patients suffer from ischemic tissue damage but treatment options are still limited. The lab has shown that ischemia stimulates satellite cells and are exploring ways to harness their angiogenic properties in vivo or through therapeutically delivered cells.

Hannah Choi is an Assistant Professor in the School of Mathematics at Georgia Tech. Her research focuses on mathematical approaches to neuroscience, with primary interests in linking structures, dynamics, and computation in data-driven brain networks at multiple scales. Before coming to Georgia Tech, she was a postdoctoral fellow at the University of Washington and also a visiting scientist at the Allen Institute for Brain Science, and spent one semester at the Simons Institute for the Theory of Computing at the University of California, Berkeley as a Patrick J McGovern Research Fellow. She received her Ph.D. in Applied Mathematics from Northwestern University and her BA in Applied Mathematics from the University of California, Berkeley.

Jay Patel, Ph.D., is an Assistant Professor in the Department of Orthopaedics at Emory and a Health Science Specialist at the Atlanta VA. Patel joined the faculty at Emory in September 2020, and his program focuses on the repair and regeneration of musculoskeletal tissues (e.g., cartilage, meniscus), with an emphasis on using micro-scale findings to drive macro-scale therapies. His lab uses a combination of biomechanics, biomaterials, mechano-biology, in vitro systems, and functional in vivo models to motivate, design, develop, and evaluate novel treatments and therapeutics for orthopaedic injuries. He received his Bachelor’s in Bioengineering from Rice University and his Ph.D. in Biomedical Engineering from Rutgers University. He then pursued his postdoctoral training at the University of Pennsylvania in the Department of Orthopaedic Surgery, working on a variety of cartilage tissue engineering and mechano-biology projects. Patel has published over 20 manuscripts, has presented at numerous international conference meetings, and won several prestigious awards, including the Excellence in Research Award (2018) from the American Orthopaedic Society for Sports Medicine. Moreover, both his graduate and postdoctoral work resulted in pending patent applications, and the formation of startup companies with active small-business funding, demonstrating his ultimate goal of translating these approaches to the clinic.